Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q1 2016 Earnings Presentation

26 slides from Sucampo Pharmaceuticals's earnings presentation, May 4, 2016

  1. Slide 1: First Quarter 2016 Corporate Update and Financial Results

    € een. First Quarter 2016 Corporate Update and Financial Results May 4, 2016

  2. Slide 2: Introductions and Forward-Looking Statements

    Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs

  3. Slide 3: Agenda

    Agenda $ sucampo Introductions and Forward-Looking Statements Corporate Update Pipeline Update Financial Update Closing Remarks Silvia Taylor Peter Greenleaf Peter Kiener, D. Phil Andrew Smith Peter Greenleaf

  4. Slide 4: Forward Looking Statement

    Forward Looking Statement $ sucampo ‘Sucampo Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. ‘These statements are based on management's current expectations and involve risks and uncer

  5. Slide 5: Q1 2016 - Peter Greenleaf, Chairman and CEO

    Q1 2016 Corporate Update Peter Greenleaf, Chairman and CEO

  6. Slide 6: Strong Financial Performance and Continued Progress Against Our Strategic Objectives

    Strong Financial Performance and Continued Progress Against * Our Strategic Objectives 2 SUCAMPO 1. Continue to deliver outstanding financial performance 2. Continue to prioritize and progress our pipeline 3. Continue to transform our company for sustained mid- and long-term growth

  7. Slide 7: Solid Financial Results

    Solid Financial Results $ sucamPo REVENUE * Q1 overall revenue grew 60% YoY to $47.2M — Increased demand for AMITIZA in U.S. and Japan — Inclusion of the results of RTU + Q1 revenue grew 18% excluding $12.4M RTU-related revenue EARNINGS + Adjusted Net Income grew 40% YoY to $9.0M + Adjusted EPS grew

  8. Slide 8: Strong U.S. AMITIZA Performance

    Strong U.S. AMITIZA Performance $ sucampo * Takeda AMITIZA net sales for royalty calc. purposes — Q1 grew 4.8% YoY to $91.7M — Royalty revenue grew 5.1% YoY to $16.5M + AMITIZA prescriptions — Q1IMS: ~360,000 TRx, increased 5% YoY — 2015 exceptionally strong year - 5% remains consistent/slightly hig

  9. Slide 9: Strong Growth Trends

    Strong Growth Trends $ 1. Continued robust demand for AMITIZA in U.S. - Unique mechanism of action — First and only brand to be approved for three types of chronic constipation 2. Takeda continues to drive strong brand promotion — New marketing campaign geared toward patient education and awareness

  10. Slide 10: Robust Japan AMITIZA Performance

    Robust Japan AMITIZA Performance $ sucampo + Sucampo revenue — Q1 grew 31% YoY to $14.5M + Volume-driven growth + Mylan remains focused on: - Sales efforts to high-volume/high-decile physicians —- Driving switches from non-Rx options to AMITIZA + AMITIZA only branded Rx for CC in Japan — Continues t

  11. Slide 11: Reaffirming 2016 Guidance

    Reaffirming 2016 Guidance $ sucampo + Total revenue: $195.0 million to $205.0 million + Adjusted net income: $45.0 million to $50.0 million + Adjusted EPS: $0.97 to $1.07 + Adjusted EBITDA: $100.0 million to $105.0 million — Guidance excludes amortization of acquired intangibles of approximately $17

  12. Slide 12: Pipeline Progress: Upcoming Milestones

    Pipeline Progress: Upcoming Milestones $ sucampo_ VAP-1 (RTU-1096) AMITIZA (lubiprostone) AMITIZA. (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) CPP-1X/sulindac combination product Cobiprostone AMITIZA (lubiprostone) Cobiprostone AMITIZA (lubiprostone) Event Top-line data from Phase 1

  13. Slide 13: Transform Business Through Business Development

    Transform Business Through Business Development $ sucampo + Exclusive option for a Phase 3 program in familial adenomatous polyposis (FAP) with Cancer Prevention Pharmaceuticals + Enter into rare and orphan disease space + Harnesses our expertise in gastroenterology + R-Tech Ueno integration progres

  14. Slide 14: Pipeline Update

    Pipeline Update Peter Kiener, D.Phil, CSO

  15. Slide 15: Product Pipeline Overview

    Product Pipeline Overview $ SUCAMPO Development Stage Program First indication hag AMITIZA cic2 Pediatric functional constipation Pa 2016 2017 Lubiprostone Pediatric functional constipation = 2018 (1); 2019 (1); Microparticle Formulation CC? (1); adutt cic (2) 2017 (2) 2018 (2) Bate Poly-amines Fami

  16. Slide 16: Lifecycle Management Programs for AMITIZA

    Lifecycle Management Programs for AMITIZA $ + Pediatric Functional Constipation (6-17 years) Recently completed enrollmentin P3 study Uses current formulation Data expected 2H16 Plan to file sNDA2H16 + Alternate Formulation Expectto initiate P3 study in adult patients with CIC 2H16 Expect data 1H17

  17. Slide 17: Cobiprostone

    Cobiprostone $ sucamPo_ + NERD/sGERD — Phase 2a data did not support advancement of cobiprostone in this indication — Data showed significant benefit in some secondary measures — Affirmed cobiprostone is well-tolerated * Consistent with P1 studies * Oral Mucositis — P2a study ongoing - Futility anal

  18. Slide 18: Additional Development Stage Programs

    Additional Development Stage Programs RTU — 1096 VAP-1 Inhibitor + Top-line results expected from Phase 1 MAD 1H16 CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP * Significant opportunity — Phase 3 asset — Orphan indication for familial adenomatous polyposis (FAP) * Clinical develo

  19. Slide 19: Financial Update

    Financial Update Andrew Smith, CFO

  20. Slide 20: Q1 Total Revenue

    Q1 Total Revenue $ sucampo “ey mz 350 4 ss ‘$Milion g 150 } 100 7 | & 50 00 12015, R-Tech inckision —AMITIZAUS Royalty = AMITIZA Japan other qi 2016

  21. Slide 21: Adjusted EBITDA

    Adjusted EBITDA $ sucampo 250 150 | $ Million 100 } 50 00 a1 2015, A-Tech inclusion Revenue contribution 212016

  22. Slide 22: Debt Position

    Debt Position | item =| As 0f 3/31/16 As of 12/31/15 Cash, Cash $157.0M ($6.5M) $163.5M Equivalents and Restricted Cash Total Debt ($235.7M) $16.7M ($252.4M) Net Debt ($78.7M) $10.2M ($88.9M)

  23. Slide 23: Reaffirming 2016 Guidance

    Reaffirming 2016 Guidance $ sucampo + Total revenue: $195.0 million to $205.0 million + Adjusted net income: $45.0 million to $50.0 million + Adjusted EPS: $0.97 to $1.07 + Adjusted EBITDA: $100.0 million to $105.0 million — Guidance excludes amortization of acquired intangibles of approximately $17

  24. Slide 24: Closing Remarks

    Closing Remarks Peter Greenleaf, Chairman and CEO

  25. Slide 25: 2016 Areas of Focus

    2016 Areas of Focus $ sucampo 1. Deliver outstanding financial performance: driven by top and bottom-line growth 2. Advance pipeline programs 3. Evaluate additional opportunities for accelerated /sustainable mid-to- long- te

  26. Slide 26: Q&A Session

    Q&A Session

Sucampo Pharmaceuticals — Q1 2016 Earnings Presentation on 6ix